Maze Therapeutics, Inc. (MAZE)
MAZE moved a median of +0.50% 30 minutes after news, and +0.33% by the close. How MAZE actually reacts to news — the realized, point-in-time move the market made, measured across 215 labeled events over the last three years with zero look-ahead.
MAZE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 214 |
| 30-min | +0.50% | 55% | 214 |
| 60-min | -0.26% | 49% | 214 |
| to close | +0.33% | 52% | 214 |
| Middle 50% of MAZE reactions | -1.05% to +2.19% |
|---|---|
| Median reaction (30-min) | +0.50% |
| Measured reactions | 215 |
Half of all Maze Therapeutics, Inc. news events land between -1.05% and +2.19% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MAZE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | +1.13% | 69% | +0.86% |
| Coverage initiations | 27 | +3.07% | 70% | -1.23% |
| Rating reiterations | 26 | +0.16% | 58% | -0.31% |
| Price-target raises | 10 | -0.51% | 30% | -0.54% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how MAZE ranks against every other measured name →
That’s how MAZE usually reacts — get an email when it moves on news →Email me when MAZE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MAZE's baseline. Nothing else.
Recent MAZE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Maze Therapeutics, Inc. For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026 | Press release | GlobeNewswire | +0.08% | -0.19% | |
| Maze Therapeutics to Participate in Three Upcoming Investor Conferences | Press release | GlobeNewswire | +3.02% | +0.87% | |
| Form 8-K Maze Therapeutics, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.91% | +4.45% | |
| Maze Therapeutics Announces Appointments to Its Board of Directors | Press release | GlobeNewswire | -1.27% | -1.06% | |
| Form 10-Q Maze Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.56% | +0.18% | |
| Form 8-K Maze Therapeutics, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -1.56% | +0.18% | |
| Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights | Press release | GlobeNewswire | -1.56% | +0.18% | |
| Form 8-K Maze Therapeutics, Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -2.00% | +0.46% | |
| Maze Therapeutics to Participate in Two Upcoming Investor Conferences | Press release | GlobeNewswire | -0.23% | -1.14% | |
| Form 8-K Maze Therapeutics, Inc. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | +2.21% | |
| Form EFFECT Maze Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.82% | -1.60% | |
| Form 10-Q Maze Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.57% | +3.69% | |
| Form 8-K Maze Therapeutics, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -2.57% | +3.69% | |
| Form POS AM Maze Therapeutics, Inc. | SEC filing · Form POS | SEC EDGAR | -2.57% | +3.69% | |
| Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights | Press release | GlobeNewswire | -2.57% | +3.69% | |
| Form ARS Maze Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.19% | -0.16% | |
| Form DEF 14A Maze Therapeutics, Inc. For: Jun 08 | SEC filing · Form DEF | SEC EDGAR | +0.19% | -0.16% | |
| Form DEFA14A Maze Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.19% | -0.16% | |
| Form 8-K Maze Therapeutics, Inc. For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | -1.63% | |
| Maze Therapeutics Announces $150 Million Registered Offering | Press release | GlobeNewswire | +3.00% | -3.04% | |
| Form 10-K Maze Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.43% | -20.68% | |
| Form 8-K Maze Therapeutics, Inc. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | -1.43% | -20.68% | |
| Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease | Press release | GlobeNewswire | -1.43% | -20.68% | |
| Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights | Press release | GlobeNewswire | -1.43% | -20.68% | |
| Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | +0.42% | +3.60% | |
| Form 8-K Maze Therapeutics, Inc. For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | -5.89% | |
| Form S-3ASR Maze Therapeutics, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | -0.40% | -5.89% | |
| Form S-8 Maze Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.40% | -5.89% | |
| Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | -0.46% | -0.17% | |
| Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.33% | -2.87% | |
| Form 10-Q Maze Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.12% | -4.25% | |
| Form 8-K Maze Therapeutics, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -1.12% | -4.25% | |
| Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Press release | GlobeNewswire | -1.12% | -4.25% | |
| Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week | Press release | GlobeNewswire | -1.17% | -1.20% | |
| Maze Therapeutics to Participate in Four Upcoming Investor Conferences | Press release | GlobeNewswire | +2.20% | -1.67% | |
| Form S-1 Maze Therapeutics, Inc. | SEC filing · Form S-1 | SEC EDGAR | +3.54% | +7.05% | |
| Form 8-K Maze Therapeutics, Inc. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | +1.08% | -0.97% | |
| Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors | Press release | GlobeNewswire | +1.08% | -0.97% | |
| Form 8-K Maze Therapeutics, Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +2.37% | +17.54% | |
| Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement | Press release | GlobeNewswire | +2.37% | +17.54% | |
| Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) | Press release | GlobeNewswire | +2.37% | +17.54% | |
| Form 8-K Maze Therapeutics, Inc. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | +4.64% | |
| Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer | Press release | GlobeNewswire | -0.41% | +4.64% | |
| Form 10-Q Maze Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.86% | |
| Form 8-K Maze Therapeutics, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.86% | |
| Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Press release | GlobeNewswire | +0.00% | -2.86% | |
| Maze Therapeutics to Participate in Two Upcoming Investor Conferences | Press release | GlobeNewswire | +0.38% | -3.77% | |
| Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference | Press release | GlobeNewswire | -1.12% | +5.09% | |
| Form 10-Q Maze Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +4.66% | +4.76% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MAZE section they belong to.
Where else MAZE is measured.
MAZE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Maze Therapeutics, Inc.'s median reaction calculated?
Every labeled MAZE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 215 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of MAZE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MAZE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.